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ABSTRACT 
 
 
 
Natamycin (NT) is a commercially available antifungal drug used for the treatment of fungal 
keratitis, an infection which affects the clear corneal surface and its associated layers.  Currently, 
NT is available commercially as a 5% w/v ophthalmic suspension, to be administered 
topically. The main objective of the present investigation was to develop and 
evaluate the natamycin loaded nanosuspension (NT-NS), as well as it‘s corresponding in-situ 
gel (NT-NS-GG), for the treatment of fungal keratitis. NT-NS was prepared using 
homogenization technique and optimized based on size, PDI, zeta potential (ZP), assay and 
process stability. Further, optimized NT-NS was modified into an in-situ gel with the addition of 
0.2% gellan gum as a gelling agent and evaluated for rheological properties. In vitro release and 
trans corneal permeation studies were performed. Differential scanning calorimetry studies 
showed no interaction between the drug and other excipients being formulated into a NS. Particle 
size, PDI, ZP and assay of the optimized NT-NS formulation (formulation LP1) were 586. ± 61.3, 
0.447 ± 0.12, -38.97 and 107 ± 0.6%, respectively. LP1 formulation was stable for up to 4 weeks 
under refrigerated and at room temperature conditions. In-situ gels showed satisfactory 
rheological properties, prolonged drug release and permeation through rabbit corneas. The 
results suggest that NT loaded NS could be an alternative topical ocular dosage form. 
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CHAPTER I 
INTRODUCTION 
 
Eyes are one of the most important and complex sensory organs; they act as a gateway to 
collect external images and transmit them to the brain as signals through the optic nerve [1]. This 
maintains a connection between the body and the surroundings. Its visual capabilities may be 
affected by bacterial, viral or fungal infections of the eye as well as age related disorders.  The 
complex anatomy, physiology and biochemistry of the eye, renders this organ highly impervious 
to drugs/treatment [1]. 
The eyes can broadly be classified into two segments: the posterior segment and the anterior 
segment. The anterior segment consists of the cornea, conjunctiva, aqueous humor, iris, ciliary 
body and the lens. The sclera, choroid, Bruch’s membrane, retinal pigmented epithelium, neural 
retina and vitreous humor make up the posterior segment of the eye [1]. The anterior segment of 
the eye occupies one-third of the eye.   
Anatomy and Physiology of the eye. 
Anterior segment  
The cornea is known to be the largest penetration barrier, inhibiting the passage of drug 
into the eye, avascular in nature and comprising of 5 layers. The primary diffusional barrier is the 
corneal epithelium, which controls the entry of drug into the eye [2]. The external surface of the 
cornea is exposed to the environment, and is covered by a tear film; its inner surface is in contact 
with the aqueous humor [1]. The efficiency of drug penetration across the cornea is governed by 
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various factors, such as the integrity of the cornea, the properties of the drug and the type 
of formulation the drug is administered in [2]. 
 The conjunctiva is a thin, semitransparent, elastic, mucous secreting tissue forming the 
lining of the upper and lower eyelids [1]. A thin vascular layer known as the ciliary body 
contains the ciliary muscle responsible for adjusting the shape of the lens to focus on an object 
[3]. The epithelial cells of the ciliary body continuously produce an alkaline ocular fluid, at a rate 
of 2.5µL/min, known as the aqueous humor which supplies nutrients to the cornea and lens  
Located at the posterior region of the cornea, the iris consists of 3 layers. the endothelium, 
stroma and the epithelium [1]. The central aperture is a pupil which is controlled by the iris, 
regulating the amount of light entering the eye [4].    
The ciliary body is located anterior to the iris and has three major functions: secreting 
aqueous humor, adjusting focus and draining aqueous humor [1].  
Located behind the iris and the pupil, the lens is transparent and biconcave in nature. The 
anterior part is in contact with the aqueous humor while the posterior part is in contact with the 
vitreous humor [1].    
Posterior segment of the eye  
The sclera also known as the ‗white of the eye‘ is an elastic tissue present below the 
conjunctiva. It gives the eyeball its shape and protects the internal organs of the eye from 
damage [5]. The sclera is made up of a network of collagen fibers responsible for the scattering 
of the visible light.  
Present between the peripheral sclera and the inner retinal membrane, the choroid is made 
of the outer suprachoroid, which is 6-10 layers thick, the vascular layer below 
the suprachoroid and the Bruch‘s membrane which is the innermost layer consisting of 
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photoreceptor cells [1].   Each eye of an individual contains approximately 3.5 million non-
dividing retinal pigmented epithelium cells (RPE). It plays a vital role in the functioning of 
photoreceptors and is essential for maintaining visual function [1].  
Light sensitive neural cells line the inner lining of the eyeball which makes up the 
neural retina. The neural retina interacts with the external environment by transmitting sensory 
information to the brain.  Rods and cones are collectively known as the photoreceptor cells. 
These cells capture and convert the collected photons into neural signals. The cone cells help in 
distinguishing between black and white colors in dim light while the rod cells differentiate colors 
in bright light [1].   
A gel like fluid is present between the lens and the retina known as the vitreous humor. 
The vitreous humor is 99.9% water,0.01% of collagen fibrils, hyaluronic acid and ions, and aids 
in maintaining the structure of the eye.  
Topical dosage forms 
Topical administration is preferred for treating disorders of the anterior segment of the 
eye as it offers a few major advantages [6].  It helps in localizing the drug effects by minimizing 
systemic exposure. It‘s ease of administration makes it convenient for self-administration by 
patients and is a painless method which in turn leads to increased patient compliance [6]. Due to 
these reasons ophthalmic drugs are primarily administered topically, in the form of solutions, 
suspensions, and ointments. However, ocular tissues are biologically protected from external 
toxic elements by a variety of mechanisms [6]. The most prominent mechanism is tear secretion, 
which continuously flushes the surface of the eye. There is also the surface epithelium which is 
almost impermeable, and possesses an active efflux-transport system [6].   The major goal in 
ocular therapeutics is to circumvent these structural obstacles and protective mechanisms in 
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order to elicit the desired pharmacological responses [7]. Physiological barriers to topically 
administered drugs are present mainly in the precorneal and corneal regions.  Precorneal factors 
such as lacrimation, dilution, and conjunctival absorption cause loss of more than 90% of the 
topically administered formulation [1]. Due to these formidable physiological barriers, frequent 
dosing is often necessitated to achieve satisfactory therapeutic results. This results in a pulsating 
dosing pattern with extreme fluctuations of drug concentration in the ocular region. These 
extreme fluctuations may cause local or systemic adverse effects. For maximum bioavailability 
of the topically administered drug, it is thus important that duration of contact with the cornea be 
increased. 
Fungal keratitis  
Fungal keratitis (keratomycosis) is a fungal infection of the cornea the incidence being between 6% 
-20% of all microbial keratitis cases, depending on the geographic location.  It primarily affects 
the corneal epithelium and stroma, although the endothelium and anterior chamber of the eye 
may get involved in more severe cases. Fungal keratitis is common in tropical countries 
compared to the temperate regions. Its incidence in developed countries is reported to be 
increasing due to the widespread use of contact lenses. Infections due to filamentous fungi such 
as Fusarium and Aspergilillus are found to be more common in tropical regions while temperate 
regions show a higher incidence of yeast infections such as Candida [8].   
The main outcomes desired in an ophthalmic therapy for fungal keratitis is the resolution of the 
infection as rapidly as possible to give way to good visual outcome and to eliminate the need for 
therapeutic keratoplasty or  permanent loss of vision[8]. Fungal keratitis is a challenging 
ophthalmologic condition that requires a high level of suspicion and aggressive treatment to 
prevent untoward outcomes [9].  
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Natamycin (NT) has been one of the mainstays in the treatment of fungal keratitis [10]. NT 
suspension is currently the only FDA approved ophthalmic antifungal formulation.   
Natamycin is stable at pH 5-9. At pH levels higher or lower, they are found to undergo 
saponification and/or bond cleavage which leads to instability and hence loss of antifungal 
activity. NT is also susceptible to photo-oxidation and hence should be stored in the dark [10].   
NT shows antifungal activity against both filamentous as well as non-filamentous fungal species, 
with potent activity against the filamentous species compared to other antifungal agents. It is 
found to be potent against Aspergillus and Fusarium species apart from Candida species. NT has 
low retention at the ocular surface which requires it to be frequently administered. Despite these 
limitations, NT has shown efficacy in treating superficial ophthalmic fungal infections mainly 
due to its trans-corneal penetration capability [10].  
Currently, a formulation of NT (Natacyn
®
 Alcon Laboratories, Fort Worth, TX) is available 
commercially for the treatment of fungal keratitis. It is available as an aqueous suspension 
containing 5% NT (50 mg/mL); pH adjusted to 5-7.5 to prevent chemical instability of NT. 
Benzalkonium chloride is added to the suspension to prevent bacterial growth [10].    Its higher 
penetration across intact cornea upon topical administration and its broad spectrum of activity 
makes natamycin the forerunner in the treatment of fungal keratitis. NT eye-drops have, thus, 
been the primary option for superficial corneal infections. Other antifungals such as 
Amphotericin B. echinocandin, and azoles are also used off label as a second-line of treatment 
[10].  
Nanosuspensions (NS) are sub-micron colloidal dispersions of pure particles of drug, stabilized 
by surfactants. The particle size of the drug in the dispersed phase ranges from 100 to 1000 nm 
[11]. Surfactants act as stabilizing agents by lowering the surface tension between the dispersed 
6 
 
drug molecules and the dispersion liquid, allowing the formulation to stabilize [12]. 
Nanosuspensions contain particles of 100% pure drug devoid of any carriers or vehicles 
[13].  Hence a high drug loading in nanosuspensions could result in highly efficient drug 
transportation into the cells leading to high therapeutic concentrations, which in turn would 
maximize the pharmacological effects.  However, surfactant-stabilized suspensions must 
possess sufficiently high energy barriers to prevent the suspended particles from coming close 
together and agglomerating.   
PEGylated natamycin NLCs (nanostructured lipid carriers) with 0.3% drug load [14] and ion 
sensitive in situ gels of natamycin bilosomes [15] have been previously reported. The optimized 
PEGylated NLC (0.3%) had a particle size with a narrow PDI, high NT entrapment and drug 
content. In the in vitro studies, the NLC formulation also showed an improved transcorneal 
permeation and flux compared to the Natacyn
®
 (5%) the marketed suspension, as well as 
concentrations statistically similar to Natacyn
® 
in the inner ocular tissues [14]. 
The optimized NT bilosomes (NB) showed a 6-9 fold enhancement of transcorneal flux and 
ocular penetration. The in situ gel with 0.3% gellan gum was found to be cytocompatible with 
the desired viscoelastic and adhesive properties [15]. 
 
In situ forming gels are liquids at the time of instillation into the eye, but then undergoes 
rapid gelation in the cul-de-sac of the eye to form viscoelastic gels in response to environmental 
changes [16]. In situ gels tend to increase precorneal residence time of the drug in the cul-de-sac, 
leading to sustained release, enhanced bioavailability and reduced dosing frequency.  The main 
reason for the popularity of in situ gels is the ease of administering accurate quantities compared 
to pre-gelled formulation [17]. Electrolyte sensitive in situ gel systems undergo a gel-sol 
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transformation when in contact with mono or divalent cations in the tear fluid, particularly 
Na
+,
 Mg
2+
 and Ca
2+
, thus forming a gel on the ocular surface [17]. Naturally 
occurring polysaccharides have been used as a matrix to obtain sustained drug 
delivery [18].  Gellan gum is an anionic polysaccharide which undergoes a sol-gel transition due 
to the temperature and ionic conditions present in the tear fluid, forming an ordered state 
of gellan chains responsible for the gelling effect [18].    
A majority of the drug instilled into the eye, is drained out via reflexive blinking or through 
lacrimation. Thus, the desired formulation characteristics include prolonged pre-corneal 
residence time, non-irritating characteristics and suitable rheological properties [19].  From the 
perspective of patient compliance, a dosage form capable of maintaining contact with the cornea 
for extended periods of time, which would reduce the frequency of dosing, is desired [20].  
In the current study, we attempted to develop a  NT-NS and corresponding in situ gel (NT-NS-
GG) with gellan gum as the gelling agent. Particle size, polydispersity index, assays and zeta 
potential of the NT-NS were evaluated. The optimized NT-NS was evaluated for stability studies 
at 25°C and 4°C for 30 days.  For the NT-NS-GG, characteristics such as gelling time, gel 
retention time, viscosity of the formulation with and without the addition of simulated tear fluid 
were investigated. The optimized NT NS and NT-NS-GG were evaluated for in vitro release 
studies and transcorneal penetration studies.  
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CHAPTER II 
 
METHODOLOGY 
Materials 
 NT was purchased from Cayman Chemicals (Ann Arbor, MI). Polysorbate 80, poloxamer 
188 was purchased from Acros Organics (Morris, NJ). Laboratory grade lecithins (Fair Lawn, 
New Jersey), Tyloxapol was purchased from Sigma-Aldrich Life Science (St Louis, 
MO). Gellan gum was obtained from Alfa Aesar (Ward Hill, MA). High performance liquid 
chromatography (HPLC) grade solvents and other chemicals (analytical grade) were supplied by 
Fisher Scientific (Hampton, NH). Slide-A-Lyzer™ MINI Dialysis Device, 10K was purchased 
from Thermo Fisher (Rockford, IL). 
 
Animal tissues 
Whole eyes of male albino New Zealand rabbits were acquired from Pel-Freez 
Biologicals (AR, USA). 
 
Preparation of natamycin nanosuspension (NT-NS) and in-situ gels (NT-NS-GG)   
Selection of surfactants combination   
Two types of surfactant combinations were used: polysorbate 80 with poloxamer 188 and 
lecithin with poloxamer 188. Tyloxapol was used as a surface-active agent. PVP K 30 was used 
as a stabilizer.  
Method of Preparation of natamycin nanosuspension (NT-NS):  
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NT loaded NS were prepared using homogenization method as per the compositions in Table 1 
and 2. The surfactants along-with tyloxapol and poloxamer 188 were dissolved in sufficient 
volume of water with the aid of magnetic stirring.  On forming a clear solution, NT was added to 
the above solution and stirred at 2000 rpm on a magnetic stirrer for 5 minutes at room 
temperature. This suspension was then homogenized using a T-25 digital Ultra-Turrax at 16,000 
rpm for 5 minutes.   
Table 1: Composition of natamycin nanosuspension (NT-NS) with single surfactant 
Ingredients NT-Tylo NT-HPMC NT-Leci 
Lecithin - - 0.1% 
HPMC 4KM - 0.1% - 
Tyloxapol 0.1% - - 
Natamycin 0.3% 0.3% 0.3% 
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Table 2: Composition of natamycin nanosuspension (NT-NS) 
Ingredients LP1 LP2 TB5 TwB TP1 TP2 TP3 TP4 F1 
Natamycin 0.3% 0.3% 0.3% 0.3% 0.3% 0.3% 0.3% 0.3% 1% 
Lecithin 0.5% - 0.1% - - - - - - 
Polysorbate 
80 
- 0.1% - 0.1% 0.1% 0.5% 0.75% 1% 0.5% 
Poloxamer 
188 
0.5% 0.5% 0.1% 0.2% 0.5% 0.5% 0.5% 0.75% - 
Tyloxapol 0.1% 0.1% 0.1% 0.1% - 0.1% 0.1% 0.1% 0.3% 
PVP K 30 - - - - - - - - 1.5% 
Water Qs 10 Qs 10 Qs 10 Qs 10 
 
Qs 10 
 
Qs 10 
 
Qs 10 Qs 10 Qs 10 
 
The natamycin nanosuspension in-situ gels (NT-NS-GG) were prepared using the NT-NS 
optimized formulation and with the addition of gellan gum to sufficient quantity of water and 
stirred continuously at 30°C till a clear solution was formed. The gellan gum was then added to 
the NT-NS with constant stirring at room temperature.  
 
Characterization of NT-NS  
Measurement of particle size, polydispersity index (PDI) and zeta potential (ZP)  
The particle size and PDI of the NT-NS formulation was determined by photon 
correlation spectroscopy at 25°C and with 173° backscatter detection, in disposable folded 
capillary clear cells. The samples for analysis were prepared as follows: the formulation was 
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vortexed for a couple of seconds, 10 µL of the formulation was diluted to 1000 µL using Milli-
Q water filtered through a 0.2µ syringe filter before addition. This sample was used to measure 
particle size and PDI.   
Zeta potential (ZP) measurements were also carried out at 25°C using the laser Doppler 
velocimetry function of the same instrument.   
Quantification of natamycin - HPLC conditions   
The natamycin content in the formulations were determined by the High-Performance 
Liquid Chromatography-Ultraviolet (HPLC-UV) technique. The mobile phase consisted of a 
mixture of phosphate buffer (0.2 M, pH 5.5) and ACN (acetonitrile) in the ratio of 70:30. The 
flow rate was maintained at 1 mL/min. A C18 Phenomenex Luna® (5μ, 250 x 4.6 mm) column 
was used. The temperature for the analyses was 25°C, 20µl of the sample was injected into the 
column and the UV detection wavelength was set to 304 nm at AUFS 1.00 [14]. The HPLC 
system consisted of a Waters 717 plus auto-sampler coupled with a Waters 2487 Dual λ 
Absorbance UV detector, a Waters 600 controller pump, and an Agilent 3395 Integrator.  
Drug content of NT-NS and NT-NS-GG 
Briefly, the assay samples were prepared by diluting 100µl of the formulation to 10ml 
using methanol in calibrated volumetric flasks. Methanol was used since NT is soluble in 
methanol. The volumetric flask was then sonicated using a bath sonicator for 15 minutes. 1ml of 
this solution was then centrifuged at 13,000 rpm for 15 minutes (AccuSpin 17 R centrifuge, 
Fisher Scientific, Hampton, NH) and analyzed using the HPLC-UV method mentioned above. 
Differential Scanning Calorimetry (DSC)  
DSC of pure natamycin and NT-NS was obtained using TA instruments DSC 25 
Discovery series, New Castle, DE) equipped with Trios manager software. The NT-NS was 
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filtered using a vacuum filter apparatus with a 0.2µm filter (Isopore
TM 
Membrane Filters, Merck 
Millipore Ltd.). The deposit on the filter was allowed to dry overnight and then gently scrapped 
off of the filter. Approximately 5mg of solid sample was sealed in the T0 aluminum pans and 
loaded into the DSC. The samples were scanned from 40 to 200°C at a heating rate of 10°C/min  
Terminal steam sterilization  
Natacyn® and the optimized formulation were subjected to terminal steam sterilization. 2 
ml of Natacyn® and NT-NS were taken in glass vials and placed in the autoclave (Tuttnauer 
Autoclave-Steam Sterilizer 3850 EL). A sterilization cycle of 121°C for 15 minutes at 15 psi [21] 
was used. The formulations were examined for their physical appearances and compared to the 
formulations prior to sterilization. 
Characterization of NT-NS in situ gel (NT-NS-GG)  
In vitro gelling behavior   
The in vitro gelling capacity of NT-NS-GG was determined by the gel formation time 
(GFT) and the gel residence time (GRT). These two parameters were visually inspected [15]. 
Briefly, 50 µL of the formulation was added to 2 mL of freshly prepared simulated tear 
fluid (STF); pH 7 ± 0.2 at 34°C. The composition of the STF was as follows: 0.678% sodium 
chloride, 0.0084% calcium chloride, 0.138% potassium chloride, and 0.218% sodium 
bicarbonate in deionized water [22]. This vial was maintained at 34°C in a shaking water bath 
(Precision
TM
, Fisher Scientific) at 1000rpm for 12 hours. The time taken for the formulation to 
gel was noted down as the GFT.  The vial was visually inspected periodically and the time 
required to break the gel formed recorded as the GRT.   
Rheological studies:  
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The viscosity of NT-NS-GG was measure using the Brookfield cone and plate viscometer 
(Model: LVDV-II + Pro Viscometer, Middleboro, MA). It was calibrated before measuring the 
viscosity of the in-situ gel. About 500 µL of the in-situ gel formulation was added to the center 
of the spindle, and the gap was adjusted accordingly. The spindle used was 52. The cup was 
maintained at 25°C. A CPE-52 Cone/Spindle was operated at 1, 2 and 5 rpm and the viscosity 
recorded using the Rheocalc software. The in-situ gel was evaluated first by itself and then with 
the addition of STF, wherein the formulation and STF were added in the ratio of 50:7.  
 In vitro release studies:  
In vitro release studies were carried out using a multi-station hot plate magnetic stirrer (RT 10 
power, IKA® WERKE, Wilmington, NC). Briefly, 20 mL of isotonic phosphate buffer saline 
(IPBS) (pH 7.4), containing 2.5% randomly methylated β-cyclodextrin (RMβCD), was taken in 
scintillation vials. The lower end of the 10K membrane (Slide-A-Lyzer™ MINI dialysis), was 
submerged into the receiving medium (IPBS+ RMβCD). Once the setup reached a temperature 
of 34 ± 0.2°C, 200µl of the formulation was placed onto the membrane.  The setup was 
maintained at 34 ± 0.2°C,  with constant stirring for the entirety of the study. The control 
consisted of a coarse suspension of NT (3 mg/mL).  Aliquots were withdrawn from the vials at 
predetermined time intervals and replaced with equal volume of IPBS with 2.5% RMβCD. NT-
NS-GG was added, along with STF, into the membrane in the ratio of 50:7 [17]. The amount of 
drug released was quantified using the HPLC method mentioned previously. The study was 
carried out for 24 hours. 
Transcorneal studies:   
Transcorneal studies were carried out using corneas separated from whole rabbits' eye, obtained 
from Pel-Freez Biologicals® (Inc Rogers, AR, USA) shipped overnight in Hanks balanced salt 
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solution over ice. The eyes were used immediately upon arrival [22]. The cornea was excised 
and washed with Dulbecco‘s phosphate buffer saline (DPBS) (pH 7.4) prior to being mounted 
on vertical Valia-Chien cells (PermeGear, Inc®). The cornea was placed with the endothelial 
side facing the receiver chamber while the epithelial side faced the donor compartment. 200µl 
each of  NT-NS and NT-NS-GG were added to the individual donor chambers. DPBS (5ml) (pH 
7.4) with 2.5% w/v of RMβCD medium was filled into each of the receiving chambers 
maintained at 34 ± 0.2°C for the entirety of the study. Aliquots of 800 µL were withdrawn from 
the receiving chambers at predetermined time points and replenished by adding an equal volume 
of fresh medium. The study was carried out for a total time period of 3 hours.   
Data analysis of Transcorneal studies.   
The transcorneal permeation across the rabbit cornea were calculated as follows [15]. The 
cumulative amount of drug permeated M was calculated:   
 
 Where n indicates sampling point (n= 1,2,3...8 which corresponds to 15, 30, 45, 180 
minutes respectively) Vr and Vs represent volume of the medium in the receiver chamber (mL) 
and volume of the sample collected at the time point n (ml). Cr(n) indicates the concentration of 
the drug in the receiver medium at the time point n (µg/ml). The rate of NT permeation across 
the rabbit cornea was determined from the slope of cumulative amount of NT permeated vs. time 
(t).   
The flux was calculated as per equation 3:  
Flux (J) = (dM/dt)/A       (3) 
Where, M represent the cumulative amount of drug transported and A designates the surface area 
of the cornea utilized in the experiment (0.636 cm
2
)   
15 
 
The transcorneal permeability of NT is calculated from the ratio of steady-state flux (J) and the 
amount of drug added to the donor chamber (Cd) as follows  
  
Stability studies  
The optimized formulations were stored at 4°C, 25°C, and at 40°C. Samples were 
withdrawn and analyzed according to predetermined time points and changes in particle size, 
PDI and assay % were evaluated.  
Statistical analysis: 
Results were presented in their mean values ± standard deviation.  
 
 
 
. 
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CHAPTER III 
RESULTS AND DISCUSSION 
Quantification of natamycin  
NT was quantified using standard calibration plots ranging from 0.5-50 µg/mL. The standard 
curve was linear for the above range of concentration. The limit of detection and quantification 
were 0.05 and 0.1 µg/mL. The standard curves in all the assays, in vitro drug release and 
transcorneal permeation studies were linear with a coefficient of determination (r
2) ≥ 0.99. 
NT-NS  formulation development and characterization 
Natamycin loaded nanosuspensions were prepared by homogenization method. The 
selected placebos were loaded with NT and analyzed for particle size. An almost 2-fold 
increase was observed in the particle size after probe sonication. Hence, probe sonication process 
was not used for further development of NT-NS.   
The particle size of the formulation was measured prior to stirring at 2000 rpm with a magnetic 
stirrer and post homogenization using T-25 digital Ultra-Turrax for 5 minutes at 16,000 rpm. 
Table 3 summarizes the physico-chemical properties of the NT loaded nanosuspensions 
formulated after Ultra-Turrax processing.   
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Table 3: Physio-chemical characteristics-Particle size, PDI, ZP and assay of natamycin 
nanosuspension (NT-NS) (mean ± SD, n=3) 
Formulation Particle Size (nm) PDI ZP (mV) 
NT-Tylo 1237 ± 130.9 0.75 ± 0.03 -15 
NT-HPMC 2585 ± 725.2 1 -10.3 
NT-Leci 1046  ± 741.7 0.80 ± 0.169 -35.5 
LP1 586 ± 61.3 0.44 ± 0.4 -38.9 
LP2 708 ± 181.5 0.68 ± 0.0 -44.2 
TB5 929 ± 84.1 0.63 ± 0.0 -45.6 
TwB 3923 ± 1990 0.77 ± 0.1 -44.6 
TP1 3834 ± 2157.9 1± 0 -37.3 
TP2 1283 ± 200.0 0.85 ± 0.1 -33.8 
TP3 2846 ± 241.1 1±0 -40.2 
TP4 790  ± 59.8 0.71 ± 0.1 -30.8 
F1 859 ± 77.7 0.77 ± 0.0 -39.9 
 
An increase in the percentage of NT caused an increase in the particle size of the formulation. 
Formulations containing single surfactants showed a high particle size (refer Table 3), hence it 
was hypothesized that a surfactant combination would be more successful in reducing the 
particle size. Formulations containing lecithin with poloxamer 188 and polysorbate 80 with 
poloxamer 188 were formulated keeping the drug load (0.3%) and tyloxapol (0.1%) content 
constant while varying the concentration of the surfactant. Lecithin with poloxamer 188 was 
found to be a better combination compared to polysorbate 80 with poloxamer 188 as it was more 
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effective at reducing the particle size. The results suggested that a higher level of surfactants was 
needed to prevent the suspended drug particles from agglomerating.  Hence, the drug load of NT 
was kept at 0.3% during the preparation of NT-NS [22].  
Probe sonication resulted in an increase in the particle size of the formulations. The 
probe sonicator uses high energy causing the reduction in particle size, however in case of 
nanosuspensions, the high energy produced resulted in the suspended nanoparticles getting 
charged and attracted towards each other, facilitating agglomeration.  
A smaller particle size and a narrower PDI is desirable for the formulation of NS as larger 
particles may cause irritation in the eye upon instillation while a narrow PDI is indicative of  
possible long term stability owing to the decrease in Ostwald ripening [23].  
Zeta potential indicates the surface charge of the particle which could be used to predict the 
degree of repulsion present between the suspended particles [23]. 
From the twelve formulations prepared, four were selected on the basis of their particle size and 
are listed in Table 4. The formulations selected were LP1, TB5, TP4 and LP2.   
Table 4: List of formulations selected 
Parameter TP4 TB5 LP2 LP1 * 
Particle size 
(nm) 
790 ± 59.8 929 ± 84.1 708 ± 181.5 586 ± 61.3 
PDI 0.71 ± 0.1 0.63 ± 0.0 0.68 ± 0.0 0.44 ± 0.4 
ZP (mV) -30.8 -45.6 -44.2 -38.97 
Assay (%) - - - 107 ± 0.6 
*LP1 is the formulation selected for future studies. 
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The selected formulations were stored at 4°C and at 25°C. They were evaluated for 
particle size, PDI, zeta potential at periodic intervals for 30 days (n=3). Room temperature 
samples of TB5, LP2, and TP4 showed signs of deposits within 30 days of storage. The 
formulation LP1 was chosen for further evaluation as it did not show any signs of deposits and 
possessed the lowest particle size amongst the NT loaded formulations.  
Stability studies  
The particle size, PDI, ZP and assay of the NS was evaluated at regular time intervals for about 
30 days as shown in Table 5.  After 30 days of storage the formulation kept at 25°C showed an 
increase in the particle size, PDI and assay, and a decrease in the Zeta Potential (ZP). The 
particle size and ZP was reduced upon storage at 4°C while the PDI was fairly constant. Hence it 
could be inferred that storing the NS at 4°C was beneficial in retarding the particle size growth, 
which in turn kept the PDI uniformly distributed, conferring stability to the formulation.  
Table 5: Stability studies of optimized NT-NS (LP1) formulation at 4°C and 25°C (mean ± 
SD n=3). 
Formulation Day 1 Day 30 
NT-NS 25°C 4°C 
Particle size (nm) 586 ± 61.3 620 ± 45.2 522 ± 40.9 
PDI 0.44 ± 0.4 0.52 ± 0.1 0.45 ± 0.4 
ZP (mV) -38.97 -32.13 -31.63 
Assay (%) 107 ± 0.6 118 ± 0.3 92.7±3.7 
 
The NT-NS formulation stored at 40°C degraded after 14 days of storage, the buff colored 
nanosuspension turned yellow.   
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Gellan gum is an anionic polysaccharide polymer used as an in situ gelling agent as it 
undergoes a  sol-gel transformation when in contact with the cations present in the tear fluid [15]. 
In situ gelling properties are desired to prolong the residence time in the cul-de-sac [24]. Gellan 
gum has been used previously in the preparation of NT bilosomes, and was found to be 
compatible with natamycin [15]. On addition of gellan gum in NT Nanosuspension (0.3%), a 
thick gel was immediately formed which suggested that the addition of gellan gum at lower 
concentrations would be suitable. The formulation should possess optimum viscosity for it to be 
easily instilled into the eye but should contain a sufficient amount of gellan gum to form a gel 
rapidly on contact with the tear fluid. Table 6 represents the components present in the in situ gel 
formulation. 
Table 6: Composition of natamycin in situ gel (NT-NS-GG) 
Ingredients LP1 0.1% GG (%w/v) LP1 0.2% GG (%w/v) LP1 0.3% GG (%w/v) 
Natamycin 0.3  0.3 0.3 
Lecithin 0.5 0.5 0.5 
Poloxamer 188 0.5 0.5 0.5 
Tyloxapol 0.1 0.1 0.1 
Gellan Gum 0.1 0.2 0.3 
LP1 indicates the optimized nanosuspension, and GG stands for in-situ gel 
prepared using gellan gum. Each formulation was prepared for 10ml.   
Gelling capacity refers to the time taken for the formation of gel and the time it takes for the gel 
to remain intact in the tear fluid [23].  Formulations LP1 0.1% GG and LP1 0.2% GG were 
evaluated for gel formation time (GFT) and gel retention time (GRT). Both the formulations 
gelled immediately on addition to STF at 34°C, however the gel formed by LP1 0.1% GG did 
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not maintain its integrity for 12 hours.  LP1 0.2% GG was selected for further studies as it 
showed a satisfactory GFT and GRT. The outcomes of GFT, GRT and the viscosity of the 
selected formulation (LP1 0.2% GG) is represented in Table 7.  
Table 7: Rheological evaluation of natamycin in situ gel (NT-NS-GG) (n = 3) 
Formulation Gellan gum 
(%) 
Gel formation 
time (sec) 
Gel retention 
time (h) 
Viscosity 
(cP) 
Viscosity with 
STF (cP) 
LP1 0.1% GG 0.1% < 5 < 12 - - 
LP1 0.2% GG 0.2% < 5 > 12 130.2 562.9 
LP1 0.3% GG 0.3% Gelled in the 
vial 
- - - 
  
 
The spindle was operated at 1, 2 and 5 RPM respectively.   
Figure 1:  Viscosity of optimized NT-NS-GG (LP1 0.2% GG) with and without simulated 
tear fluid (STF). 
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Viscosity of the formulation is essential in determining the residence time of the drug into 
the eye [23]. Increase in the RPM (revolutions per minute) caused a linear increase in the shear 
rate. An increasing shear rate caused a decrease in the viscosity. Viscosity of LP1 0.2% GG was 
evaluated using the Brookfield Viscometer; the spindle was operated at 1, 2 and 5 RPM 
respectively. The addition of freshly prepared STF instantly increased the viscosity of the 
formulation as shown in Figure 1. The rapid increase in the viscosity of the formulation 
immediately on addition of freshly prepared STF is indicative of the fact that the gellan gum 
incorporated in the NT NS underwent a sol to gel transformation. This further confirmed the 
theory that the formulation was being activated in the presence of ions similar to those present in 
the eye.  
Differential scanning calorimetry (DSC)  
The sample of pure drug and LP1 was run form 25°C to 200°C with a gradual increase of 
10°C/min. 
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Figure 2: DSC thermogram of pure NT and optimized NT-NS (LP1) 
The DSC thermogram of pure NT and of NT-NS is portrayed in Figure 2. The DSC study was 
carried out to determine any change in the NT which may have occurred during the formulation 
process of the NS. The DSC thermogram of pure NT showed an endothermic peak at 115°C 
corresponding to the melting point of pure NT.  The thermogram of NT-NS showed a pattern 
similar to that of pure NT with the endothermic peak at around 107°C. It could be inferred from 
the DSC thermogram peaks that the formulation process used did not cause any changes in NT. 
The slight flattening of the peak in the DSC thermogram of the NS could be due to the presence 
of excipients in formulation or the presence of residual water molecules. 
Terminal steam sterilization  
The NT-NS and Natacyn® showed immediate signs of degradation after autoclaving. 
Figure 3A and 3B depicts the NT-NS and Natacyn
®
 prior to autoclave and post autoclave in 
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Figure 3. NT was proven to undergo degradation when autoclaved at 110
o
C for 20 minutes [25]. 
The buff colored formulations turned yellow-orange on autoclaving at 121°C for 15 minutes 
indicating signs of possible degradation. Analyzing the NS formulation and Natacyn
®
 for assay 
confirmed that both samples were degraded.  
      
           NT
®
 and Forml
n
 refer to Natacyn
®
 and NT-NS respectively.  
Figure 3: Pre autoclave (3A) and post autoclave (3B) images of NT nanosuspension and 
Natacyn
®
 (marketed formulation). 
Since the formulation could not withstand the autoclave conditions, it would be recommended 
that the NT-NS be formulated in an aseptic environment.  
In-vitro release study  
The study was carried out for 24 hours using 10K membrane.  Table 8 shows the in vitro release 
study profile of the NS, the in situ gel and the control.   
Table 8: In vitro drug release profiles of natamycin nanosuspension (NT-NS), in situ gel 
(NT-NS-GG) and NT control (mean ± SD, n=3) 
Time (h) In vitro drug release 
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NT-NS (LP1) NT-NS-GG (LP1 
0.2%GG) 
Control (NT-C) 
0 0 0 0 
0.5 0.94 ± 0.0 1.12 ± 0.1 1.65 ± 0.0 
1 1.56 ± 0.1 1.68 ± 0.3 2.59 ± 0.1 
2 3.37 ± 0.3 2.94 ± 0.6 4.79 ± 0.5 
4 7.21 ± 0.8 6.12 ± 1.5 9.86 ± 1.1 
6 10.96 ± 1.2 10.26 ± 2.7 17.98 ± 0.4 
12 28.17 ± 2.9 23.05 ± 4.5 34.12 ± 3.6 
24 59.73 ± 4.4 48.65 ± 8.1 80.38 ± 7.4 
 
 
Figure 4: In vitro release study of optimized NT-NS (LP1), NT-NS-GG (LP1 0.2% GG) and 
NT control formulations (mean ± SD, n=3)  
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The drug release profile of the optimized NT-NS and its corresponding NT-NS-GG was 
compared to that of NT control formulation containing 0.3% NT similar to the drug load present 
in the optimized formulation. The drug release profile for the NT-NS (LP1) and NT-NS-
GG (LP1 with 0.2% GG) is shown in Figure 4. LP1 0.2% GG showed a higher drug release 
(compared to LP1) in the initial hour of the study; however its release gradually diminished as 
the study progressed. Overall, the control formulation of NT showed the highest release (80.38 ± 
7.49%) followed by LP1 (59.73 ± 4.45%) and lastly the LP1 0.2% GG (48.65 ± 8.1%) in 24 
hours. The slow release from the NT-NS in situ gel could be due to the transformation into gel 
form on addition of the STF - leading to a sustained release of drug from the gel matrix as the 
study progressed. This slow release could be beneficial in providing a rapid initial release 
followed by a sustained release of NT which could potentially lead to a reduced dosing 
frequency.  
Transcorneal studies  
Table 9: Transcorneal permeation studies of natamycin nanosuspension (NT-NS) and in 
situ gel (NT-NS-GG). 
 LP1 (NT-NS) LP1 0.2% GG (NT-NS-GG) 
Flux (µg/min/cm) 0.034 ± 0.0 0.047 ± 0.0 
Permeability (cm/min x 10
-5 
)  5.6 ± 0.1
 
 7.8
 
 ± 0.2
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indicates statistically significant at level of p<0.05, compared with NT-NS. 
Figure 5: In vitro transcorneal flux and apparent permeability coefficient of natamycin 
from optimized NT-NS (LP1), NT-NS-GG (LP1 0.2% GG) (mean ± SD; n=3). 
The transcorneal permeation profile is summarized in Table 10 and represented graphically in 
figure 5. At the end of 3 hours LP1 0.2% GG showed a higher mean permeability and flux 
compared to LP1. This could be due to the addition of gellan gum which may have enhanced the 
penetration of NT from the formulation. This was almost similar to the pattern observed in the in 
vitro release data conducted wherein LP1 0.2% GG showed a higher release rate compared to 
LP1 in the first hour of the study. It could be hypothesized that LP1 0.2% GG is somewhat more 
effective in delivering NT to the ocular tissues as compared to the NS.  
 
 
0
0.01
0.02
0.03
0.04
0.05
0.06
0.07
0
1
2
3
4
5
6
7
8
9
NT-NS (LP1) NT-NS-GG (LP1 0.2% GG)
F
lu
x
(µ
g
/m
in
/c
m
) 
P
er
m
ea
b
il
it
y
 *
 1
0
 -
5
  
(c
m
/m
in
) 
Transcorneal permeation studies 
Permeability Flux
 28 
 
CHAPTER IV 
CONCLUSION 
In this study, natamycin loaded nanosuspensions and its corresponding in situ gels were 
successfully formulated using lecithin and poloxamer 188 as the surfactants. The formulation 
had a better particle size with narrower PDI. The in-situ gel formulated, showed a 
higher permeation and flux in the transcorneal studies when compared to the natamycin 
nanosuspension, the in vitro release data showed a higher release from the nanosuspension 
compared to the in situ gel over a 24 hour time period. The in situ gel formulated was activated 
with the addition of simulated tear fluid, as was confirmed by the rheological studies.  
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